{"organizations": [], "uuid": "1b34e5fe711e24c7430a3e4372f40bd125676c70", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 3, "shares": 3, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180302.html", "section_title": "Archive News &amp; Video for Friday, 02 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/biogen-zinbryta/biogen-abbvie-withdraw-multiple-sclerosis-drug-zinbryta-idUSL4N1QK44B", "country": "US", "domain_rank": 408, "title": "Biogen, AbbVie withdraw multiple sclerosis drug Zinbryta", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.703, "site_type": "news", "published": "2018-03-02T18:40:00.000+02:00", "replies_count": 0, "uuid": "1b34e5fe711e24c7430a3e4372f40bd125676c70"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/biogen-zinbryta/biogen-abbvie-withdraw-multiple-sclerosis-drug-zinbryta-idUSL4N1QK44B", "ord_in_thread": 0, "title": "Biogen, AbbVie withdraw multiple sclerosis drug Zinbryta", "locations": [], "entities": {"persons": [{"name": "zinbryta", "sentiment": "none"}, {"name": "akankshita mukhopadhyay", "sentiment": "none"}, {"name": "sai sachin ravikumar", "sentiment": "none"}], "locations": [{"name": "zinbryta", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "abbvie inc", "sentiment": "negative"}, {"name": "biogen inc", "sentiment": "negative"}, {"name": "biogen", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 2 (Reuters) - Biogen Inc and AbbVie Inc have withdrawn their multiple sclerosis drug worldwide due to safety issues, the companies said on Friday.\nThe withdrawal of marketing authorizations for the drug, Zinbryta, followed reports of inflammation of the membranes of the brain in some patients.\nZinbryta, a self-administered, under-the-skin injection designed to treat adults with relapsing forms of multiple sclerosis was approved by U.S. regulators in 2016. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sai Sachin Ravikumar)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-02T18:40:00.000+02:00", "crawled": "2018-03-03T17:40:41.037+02:00", "highlightTitle": ""}